Therapy - Antiviral
"Lamivudine and Hepatitis B."
Published in Blood Weekly, August 28th, 1995
According to an abstract submitted by the author to the 19th International Congress of Chemotherapy, held July 16-21, 1995, in Montreal, Quebec, Canada, "There are approximately 300 million chronic carriers of hepatitis B worldwide. The carrier state is a significant risk factor for the development of cirrhosis and hepatocellular carcinoma. Lamivudine [(-) enantiomer of 2',3' dideoxy,3'thiacytidine] is a potent antiviral agent for hepatitis B. Oral lamivudine at doses of 100 mg or greater per day significantly reduced serum HBV-DNA in patients with chronic hepatitis B. In one-month treatment studies, the virus HBV-DNA reappeared in most patients when therapy was discontinued. Studies...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (1995-08-28)
More Articles from Blood Weekly
- Epidemiology
HTLV-II Accounts for Most of the HTLV Infections in U.S. IVDUs - Transfusion
Autoimmune Disease in Women Is a Factor in RBC Alloantibody Development - Blood Banking
HIV-2 Seen in Blood Donations - Diagnosis
HEV Should Be Considered, Even in Developed Countries - Electronic Publishing
Henderson Newsletters Offered Electronically or by E-mail - Immunology
Recombinant Human IL-6 Related Anemia Rapid, but Reversible - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
